AstraZeneca PLC Key Executives
This section highlights AstraZeneca PLC's key executives, including their titles and compensation details.
Find Contacts at AstraZeneca PLC
(Showing 0 of )
AstraZeneca PLC Earnings
This section highlights AstraZeneca PLC's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
April 29, 2025
Time:
Before Market
Est. EPS:
$2.19
Status:
Unconfirmed
Last Earnings Results
Date:
February 06, 2025
EPS:
$2.09
Est. EPS:
$2.07
Revenue:
$11.90B
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-06 | $2.07 | $2.09 |
| Read Transcript | Q3 | 2024 | 2024-11-12 | $1.49 | $2.08 |
| Read Transcript | Q2 | 2024 | 2024-07-25 | $1.96 | $1.98 |
| Read Transcript | Q1 | 2024 | 2024-04-25 | $1.91 | $2.06 |
| Read Transcript | Q4 | 2023 | 2024-02-08 | $1.49 | $1.45 |
| Read Transcript | Q3 | 2023 | 2023-11-09 | $1.62 | $1.73 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Healthcare
Drug Manufacturers - General
$11608.00
Stock Price
$179.99B
Market Cap
-
Employees
Cambridge, None
Location
Financial Statements
Access annual & quarterly financial statements for AstraZeneca PLC, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $54.07B | $45.81B | $44.35B | $37.42B | $26.62B |
| Cost of Revenue | $10.21B | $8.04B | $12.39B | $12.44B | $5.30B |
| Gross Profit | $43.87B | $37.77B | $31.96B | $24.98B | $21.32B |
| Gross Profit Ratio | 81.12% | 82.40% | 72.06% | 66.80% | 80.09% |
| Research and Development Expenses | $13.58B | $10.94B | $9.76B | $9.74B | $5.99B |
| General and Administrative Expenses | $19.98B | $19.22B | $- | $- | $- |
| Selling and Marketing Expenses | $555.00M | $539.00M | $18.95B | $15.68B | $11.69B |
| Selling General and Administrative Expenses | $20.53B | $18.02B | $18.95B | $15.68B | $11.69B |
| Other Expenses | $-252.00M | $618.00M | $-514.00M | $-1.49B | $-1.53B |
| Operating Expenses | $33.86B | $29.58B | $28.20B | $23.92B | $16.16B |
| Cost and Expenses | $44.07B | $37.62B | $40.59B | $36.36B | $21.45B |
| Interest Income | $458.00M | $301.00M | $95.00M | $43.00M | $87.00M |
| Interest Expense | $1.74B | $1.59B | $1.35B | $1.30B | $1.31B |
| Depreciation and Amortization | $6.69B | $4.93B | $5.25B | $4.10B | $2.90B |
| EBITDA | $17.12B | $13.91B | $9.09B | $5.11B | $8.08B |
| EBITDA Ratio | 31.66% | 30.37% | 21.03% | 20.22% | 31.45% |
| Operating Income | $10.00B | $8.19B | $3.76B | $1.06B | $5.16B |
| Operating Income Ratio | 18.50% | 17.88% | 8.47% | 2.82% | 19.39% |
| Total Other Income Expenses Net | $-1.31B | $-1.29B | $-1.26B | $-1.32B | $-1.25B |
| Income Before Tax | $8.69B | $6.90B | $2.50B | $-265.00M | $3.92B |
| Income Before Tax Ratio | 16.07% | 15.06% | 5.64% | -0.71% | 14.71% |
| Income Tax Expense | $1.65B | $938.00M | $-792.00M | $-380.00M | $772.00M |
| Net Income | $7.04B | $5.96B | $3.29B | $112.00M | $3.20B |
| Net Income Ratio | 13.01% | 13.00% | 7.41% | 0.30% | 12.01% |
| EPS | $4.53 | $3.81 | $2.12 | $0.08 | $2.44 |
| EPS Diluted | $4.51 | $3.81 | $2.11 | $0.08 | $2.44 |
| Weighted Average Shares Outstanding | 1.55B | 1.56B | 1.55B | 1.42B | 1.31B |
| Weighted Average Shares Outstanding Diluted | 1.56B | 1.56B | 1.56B | 1.43B | 1.31B |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.89B | $13.56B | $12.94B | $12.68B | $12.02B | $11.49B | $11.42B | $10.88B | $11.21B | $10.98B | $10.77B | $11.39B | $12.01B | $9.87B | $8.22B | $7.32B | $7.41B | $6.58B | $6.28B | $6.35B |
| Cost of Revenue | $2.73B | $3.08B | $2.18B | $2.22B | $2.31B | $2.10B | $1.96B | $1.91B | $2.90B | $2.98B | $3.00B | $3.51B | $4.62B | $3.76B | $2.19B | $1.86B | $1.52B | $1.37B | $984.00M | $1.42B |
| Gross Profit | $12.17B | $10.48B | $10.76B | $10.46B | $9.72B | $9.40B | $9.46B | $8.97B | $8.31B | $8.00B | $7.77B | $7.88B | $7.39B | $6.11B | $6.03B | $5.46B | $5.88B | $5.21B | $5.29B | $4.93B |
| Gross Profit Ratio | 81.70% | 77.30% | 83.10% | 82.50% | 80.80% | 81.80% | 82.80% | 82.50% | 74.10% | 72.80% | 72.20% | 69.20% | 61.50% | 61.90% | 73.30% | 74.50% | 79.42% | 79.17% | 84.32% | 77.65% |
| Research and Development Expenses | $4.68B | $3.12B | $3.01B | $2.78B | $3.07B | $2.58B | $2.67B | $2.61B | $2.62B | $2.36B | $2.55B | $2.13B | $2.58B | $2.15B | $1.83B | $1.71B | $1.72B | $1.45B | $1.39B | $1.39B |
| General and Administrative Expenses | $5.41B | $5.14B | $4.93B | $4.50B | $-13.85B | $4.80B | $4.99B | $4.06B | $- | $4.28B | $- | $- | $2.29B | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $143.00M | $145.00M | $132.00M | $135.00M | $17.83B | $4.93B | $5.12B | $4.19B | $4.78B | $3.29B | $4.81B | $4.96B | $5.24B | $2.99B | $3.20B | $3.03B | $3.32B | $2.27B | $2.74B | $2.81B |
| Selling General and Administrative Expenses | $5.55B | $5.29B | $5.06B | $4.63B | $3.98B | $4.93B | $5.12B | $4.19B | $4.78B | $3.29B | $4.81B | $4.96B | $5.24B | $2.99B | $3.20B | $3.03B | $3.32B | $2.27B | $2.74B | $2.81B |
| Other Expenses | $-100.00M | $-25.00M | $-60.00M | $- | $- | $- | $- | $-138.00M | $-189.00M | $949.00M | $-122.00M | $-97.00M | $-2.43B | $2.30B | $-128.00M | $-1.18B | $-903.00M | $163.00M | $-121.00M | $-480.00M |
| Operating Expenses | $10.13B | $8.38B | $8.01B | $7.35B | $7.71B | $7.44B | $7.00B | $6.67B | $7.21B | $6.59B | $7.23B | $7.00B | $7.68B | $7.44B | $4.90B | $3.56B | $4.40B | $3.89B | $4.01B | $3.71B |
| Cost and Expenses | $12.86B | $11.46B | $10.19B | $9.56B | $10.02B | $9.54B | $8.96B | $8.57B | $10.11B | $9.57B | $10.23B | $10.51B | $12.30B | $11.20B | $7.09B | $5.42B | $5.92B | $5.26B | $4.99B | $5.13B |
| Interest Income | $64.00M | $183.00M | $100.00M | $111.00M | $65.00M | $101.00M | $64.00M | $78.00M | $45.00M | $15.00M | $18.00M | $17.00M | $1.00M | $15.00M | $7.00M | $20.00M | $7.00M | $7.00M | $22.00M | $51.00M |
| Interest Expense | $429.00M | $457.00M | $443.00M | $413.00M | $408.00M | $392.00M | $431.00M | $365.00M | $360.00M | $339.00M | $311.00M | $336.00M | $336.00M | $335.00M | $326.00M | $303.00M | $321.00M | $324.00M | $329.00M | $332.00M |
| Depreciation and Amortization | $2.34B | $1.82B | $1.28B | $1.25B | $874.00M | $1.28B | $1.28B | $1.50B | $1.25B | $1.33B | $1.36B | $1.31B | $2.19B | $2.79B | $753.00M | $797.00M | $797.00M | $801.00M | $710.00M | $841.00M |
| EBITDA | $4.43B | $4.10B | $4.12B | $4.57B | $2.18B | $3.33B | $3.68B | $3.89B | $2.38B | $2.56B | $1.96B | $2.20B | $1.87B | $1.12B | $1.88B | $2.71B | $2.25B | $2.09B | $1.99B | $1.94B |
| EBITDA Ratio | 29.76% | 30.24% | 31.84% | 35.24% | 24.19% | 28.94% | 22.07% | 35.74% | 10.15% | 25.12% | 17.78% | 19.30% | -2.50% | 14.87% | 22.42% | 36.99% | 20.08% | 32.37% | 31.87% | 33.18% |
| Operating Income | $2.04B | $2.11B | $2.75B | $3.12B | $1.23B | $1.95B | $2.46B | $2.55B | $-342.00M | $1.25B | $539.00M | $878.00M | $-292.00M | $-1.67B | $1.13B | $1.90B | $1.49B | $1.17B | $1.28B | $1.22B |
| Operating Income Ratio | 13.67% | 15.53% | 21.22% | 24.57% | 10.26% | 17.00% | 21.51% | 23.43% | -3.05% | 11.34% | 5.00% | 7.71% | -2.43% | -16.97% | 13.71% | 25.89% | 20.07% | 17.80% | 20.46% | 19.20% |
| Total Other Income Expenses Net | $-370.00M | $-278.00M | $-349.00M | $-315.00M | $-337.00M | $-302.00M | $-368.00M | $-287.00M | $-316.00M | $-323.00M | $-292.00M | $-325.00M | $-344.00M | $-327.00M | $-363.00M | $-287.00M | $-320.00M | $-318.00M | $-323.00M | $-285.00M |
| Income Before Tax | $1.67B | $1.83B | $2.40B | $2.80B | $897.00M | $1.65B | $2.09B | $2.26B | $778.00M | $922.00M | $247.00M | $553.00M | $-636.00M | $-2.00B | $764.00M | $1.61B | $1.17B | $853.00M | $961.00M | $935.00M |
| Income Before Tax Ratio | 11.19% | 13.48% | 18.53% | 22.08% | 7.46% | 14.38% | 18.29% | 20.79% | 6.94% | 8.40% | 2.29% | 4.86% | -5.30% | -20.28% | 9.29% | 21.97% | 15.75% | 12.97% | 15.31% | 14.72% |
| Income Tax Expense | $166.00M | $395.00M | $469.00M | $620.00M | $-62.00M | $274.00M | $268.00M | $458.00M | $-124.00M | $-720.00M | $-113.00M | $165.00M | $-290.00M | $-350.00M | $214.00M | $46.00M | $162.00M | $202.00M | $223.00M | $185.00M |
| Net Income | $1.50B | $1.43B | $1.93B | $2.18B | $960.00M | $1.37B | $1.82B | $1.80B | $901.00M | $1.64B | $360.00M | $386.00M | $-347.00M | $-1.65B | $550.00M | $1.56B | $1.01B | $648.00M | $756.00M | $780.00M |
| Net Income Ratio | 10.07% | 10.53% | 14.89% | 17.19% | 7.98% | 11.96% | 15.93% | 16.57% | 8.04% | 14.93% | 3.34% | 3.39% | -2.89% | -16.74% | 6.69% | 21.33% | 13.66% | 9.85% | 12.05% | 12.28% |
| EPS | $0.97 | $0.92 | $1.24 | $1.41 | $0.61 | $0.89 | $1.17 | $1.16 | $0.58 | $1.06 | $0.23 | $0.25 | $-0.22 | $-1.10 | $0.42 | $1.19 | $0.78 | $0.49 | $0.58 | $0.59 |
| EPS Diluted | $0.96 | $0.92 | $1.24 | $1.40 | $0.61 | $0.88 | $1.17 | $1.16 | $0.58 | $1.05 | $0.23 | $0.25 | $-0.22 | $-1.10 | $0.42 | $1.18 | $0.78 | $0.49 | $0.58 | $0.59 |
| Weighted Average Shares Outstanding | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.50B | 1.31B | 1.31B | 1.31B | 1.31B | 1.31B | 1.31B |
| Weighted Average Shares Outstanding Diluted | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.55B | 1.50B | 1.32B | 1.32B | 1.31B | 1.31B | 1.31B | 1.31B |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $5.49B | $5.84B | $6.17B | $6.33B | $7.83B |
| Short Term Investments | $166.00M | $20.00M | $239.00M | $69.00M | $160.00M |
| Cash and Short Term Investments | $5.65B | $5.86B | $6.41B | $6.40B | $7.99B |
| Net Receivables | $- | $8.41B | $7.21B | $6.03B | $3.81B |
| Inventory | $5.29B | $5.42B | $4.70B | $8.98B | $4.02B |
| Other Current Assets | $14.88B | $5.36B | $4.44B | $4.83B | $3.68B |
| Total Current Assets | $25.83B | $25.05B | $22.59B | $26.24B | $19.54B |
| Property Plant Equipment Net | $11.65B | $10.50B | $9.45B | $10.17B | $8.92B |
| Goodwill | $21.02B | $20.05B | $19.82B | $20.00B | $11.85B |
| Intangible Assets | $37.18B | $38.09B | $39.31B | $42.39B | $20.95B |
| Goodwill and Intangible Assets | $58.20B | $58.14B | $59.13B | $62.38B | $32.79B |
| Long Term Investments | $1.73B | $1.78B | $903.00M | $1.17B | $987.00M |
| Tax Assets | $5.35B | $- | $3.26B | $4.33B | $3.44B |
| Other Non-Current Assets | $1.28B | $5.65B | $1.15B | $1.07B | $1.05B |
| Total Non-Current Assets | $78.21B | $76.06B | $73.89B | $79.12B | $47.19B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $104.03B | $101.12B | $96.48B | $105.36B | $66.73B |
| Account Payables | $22.46B | $3.27B | $2.55B | $2.82B | $2.35B |
| Short Term Debt | $2.50B | $5.40B | $6.50B | $2.89B | $2.42B |
| Tax Payables | $1.41B | $2.08B | $896.00M | $916.00M | $1.13B |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $1.50B | $19.80B | $16.34B | $15.96B | $14.41B |
| Total Current Liabilities | $27.87B | $30.54B | $26.29B | $22.59B | $20.31B |
| Long Term Debt | $27.62B | $23.22B | $24.63B | $30.47B | $20.29B |
| Deferred Revenue Non-Current | $- | $7.00M | $14.00M | $26.00M | $38.00M |
| Deferred Tax Liabilities Non-Current | $3.31B | $31.00M | $2.94B | $6.21B | $2.92B |
| Other Non-Current Liabilities | $4.37B | $8.15B | $8.50B | $13.01B | $10.49B |
| Total Non-Current Liabilities | $35.30B | $31.41B | $33.13B | $43.48B | $30.78B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $63.16B | $61.95B | $59.42B | $66.08B | $51.09B |
| Preferred Stock | $- | $949.00M | $1.62B | $- | $- |
| Common Stock | $388.00M | $388.00M | $387.00M | $387.00M | $328.00M |
| Retained Earnings | $3.16B | $4.52B | $-574.00M | $1.71B | $5.30B |
| Accumulated Other Comprehensive Income Loss | $- | $- | $-1.62B | $111.00M | $881.00M |
| Other Total Stockholders Equity | $37.24B | $33.29B | $33.53B | $35.13B | $7.97B |
| Total Stockholders Equity | $40.79B | $39.14B | $37.04B | $39.27B | $15.62B |
| Total Equity | $40.87B | $39.17B | $37.06B | $39.29B | $15.64B |
| Total Liabilities and Stockholders Equity | $104.03B | $101.12B | $96.48B | $105.36B | $66.73B |
| Minority Interest | $85.00M | $23.00M | $21.00M | $19.00M | $16.00M |
| Total Liabilities and Total Equity | $104.03B | $101.12B | $96.48B | $105.36B | $66.73B |
| Total Investments | $1.90B | $1.68B | $1.14B | $1.24B | $1.15B |
| Total Debt | $30.11B | $28.62B | $29.23B | $30.78B | $20.38B |
| Net Debt | $24.63B | $22.78B | $23.07B | $24.45B | $12.55B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $5.49B | $4.80B | $6.92B | $7.84B | $5.84B | $4.87B | $5.66B | $6.23B | $6.17B | $4.46B | $4.82B | $5.76B | $6.33B | $7.07B | $15.57B | $7.64B | $7.83B | $8.07B | $5.67B | $3.41B |
| Short Term Investments | $166.00M | $133.00M | $160.00M | $180.00M | $20.00M | $244.00M | $148.00M | $230.00M | $239.00M | $440.00M | $70.00M | $61.00M | $69.00M | $82.00M | $62.00M | $129.00M | $160.00M | $374.00M | $442.00M | $752.00M |
| Cash and Short Term Investments | $5.65B | $4.93B | $7.08B | $8.02B | $5.86B | $5.12B | $5.81B | $6.46B | $6.41B | $4.90B | $4.89B | $5.82B | $6.40B | $7.15B | $15.63B | $7.76B | $7.99B | $8.45B | $6.12B | $4.17B |
| Net Receivables | $- | $- | $11.05B | $11.07B | $8.41B | $11.30B | $11.09B | $10.29B | $7.21B | $9.34B | $8.91B | $8.68B | $6.03B | $8.26B | $6.36B | $6.28B | $3.81B | $5.67B | $5.02B | $5.08B |
| Inventory | $5.29B | $5.66B | $5.67B | $5.34B | $5.42B | $5.29B | $5.05B | $4.97B | $4.70B | $5.08B | $6.22B | $7.62B | $8.98B | $10.53B | $4.76B | $4.28B | $4.02B | $3.68B | $3.56B | $3.12B |
| Other Current Assets | $14.88B | $13.56B | $1.60B | $1.16B | $5.36B | $794.00M | $884.00M | $548.00M | $4.44B | $1.29B | $902.00M | $517.00M | $4.83B | $756.00M | $527.00M | $411.00M | $3.68B | $369.00M | $229.00M | $454.00M |
| Total Current Assets | $25.83B | $24.16B | $25.39B | $25.59B | $25.05B | $22.50B | $22.84B | $22.27B | $22.59B | $20.22B | $20.92B | $22.65B | $26.24B | $26.69B | $27.27B | $18.73B | $19.54B | $18.17B | $14.93B | $12.82B |
| Property Plant Equipment Net | $11.65B | $11.51B | $10.83B | $10.62B | $10.50B | $9.70B | $9.62B | $9.60B | $9.45B | $9.23B | $9.63B | $10.02B | $10.17B | $10.16B | $9.03B | $8.85B | $8.92B | $8.36B | $8.11B | $7.99B |
| Goodwill | $21.02B | $21.14B | $21.06B | $19.98B | $20.05B | $19.94B | $19.96B | $20.00B | $19.82B | $19.71B | $19.82B | $19.96B | $20.00B | $20.08B | $11.80B | $11.77B | $11.85B | $11.71B | $11.64B | $11.57B |
| Intangible Assets | $37.18B | $39.39B | $39.43B | $38.83B | $38.09B | $37.69B | $38.33B | $39.29B | $39.31B | $39.59B | $39.90B | $41.27B | $42.39B | $44.10B | $20.01B | $20.35B | $20.95B | $20.61B | $19.73B | $19.72B |
| Goodwill and Intangible Assets | $58.20B | $60.53B | $60.49B | $58.81B | $58.14B | $57.63B | $58.29B | $59.29B | $59.13B | $59.29B | $59.72B | $61.23B | $62.38B | $64.19B | $31.80B | $32.11B | $32.79B | $32.32B | $31.37B | $31.29B |
| Long Term Investments | $1.73B | $2.01B | $1.87B | $1.51B | $1.66B | $1.05B | $995.00M | $1.00B | $903.00M | $662.00M | $1.11B | $1.18B | $1.17B | $1.50B | $1.06B | $931.00M | $1.03B | $841.00M | $1.18B | $768.00M |
| Tax Assets | $5.35B | $5.34B | $- | $4.62B | $4.72B | $4.06B | $3.74B | $3.50B | $3.26B | $3.44B | $4.14B | $4.20B | $4.33B | $3.70B | $3.72B | $3.51B | $3.44B | $3.24B | $3.13B | $2.96B |
| Other Non-Current Assets | $1.28B | $1.37B | $5.76B | $1.14B | $1.05B | $1.16B | $1.06B | $1.03B | $1.15B | $1.34B | $1.06B | $1.01B | $1.07B | $983.00M | $751.00M | $793.00M | $1.01B | $1.18B | $1.21B | $1.38B |
| Total Non-Current Assets | $78.21B | $80.77B | $78.95B | $76.70B | $76.06B | $73.58B | $73.70B | $74.42B | $73.89B | $73.96B | $75.66B | $77.63B | $79.12B | $80.53B | $46.37B | $46.19B | $47.19B | $45.95B | $45.00B | $44.39B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $104.03B | $104.92B | $104.34B | $102.29B | $101.12B | $96.09B | $96.54B | $96.69B | $96.48B | $94.19B | $96.58B | $100.27B | $105.36B | $107.22B | $73.64B | $64.93B | $66.73B | $64.11B | $59.93B | $57.21B |
| Account Payables | $22.46B | $21.68B | $20.46B | $19.70B | $3.27B | $19.72B | $18.93B | $18.42B | $2.55B | $16.84B | $16.98B | $17.04B | $2.82B | $17.76B | $16.84B | $16.50B | $2.35B | $13.41B | $12.03B | $12.63B |
| Short Term Debt | $2.50B | $1.57B | $5.41B | $6.42B | $6.39B | $6.51B | $5.67B | $4.69B | $6.50B | $6.54B | $3.31B | $3.15B | $2.89B | $3.93B | $3.80B | $3.15B | $2.42B | $3.59B | $4.17B | $2.50B |
| Tax Payables | $1.41B | $1.47B | $1.52B | $1.63B | $2.08B | $1.16B | $1.20B | $1.20B | $896.00M | $1.09B | $981.00M | $1.12B | $916.00M | $987.00M | $780.00M | $994.00M | $1.13B | $1.32B | $1.38B | $1.26B |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $987.00M | $780.00M | $994.00M | $-11.92B | $1.32B | $1.38B | $1.26B |
| Other Current Liabilities | $1.50B | $1.20B | $1.17B | $1.15B | $18.81B | $1.19B | $567.00M | $546.00M | $16.34B | $377.00M | $541.00M | $1.42B | $15.96B | $972.00M | $802.00M | $875.00M | $14.41B | $621.00M | $612.00M | $649.00M |
| Total Current Liabilities | $27.87B | $25.93B | $28.57B | $28.90B | $30.54B | $28.59B | $26.38B | $24.86B | $26.29B | $24.85B | $21.82B | $22.74B | $22.59B | $23.65B | $22.22B | $21.51B | $20.31B | $18.94B | $18.18B | $17.04B |
| Long Term Debt | $27.62B | $29.99B | $28.23B | $28.27B | $23.26B | $23.04B | $25.12B | $27.78B | $24.63B | $24.74B | $28.08B | $29.59B | $30.47B | $30.46B | $26.09B | $19.34B | $20.29B | $21.02B | $17.95B | $18.48B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $7.00M | $- | $- | $- | $14.00M | $- | $- | $- | $26.00M | $- | $- | $- | $38.00M | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $3.31B | $3.57B | $- | $2.62B | $2.84B | $2.75B | $2.80B | $2.79B | $2.94B | $3.48B | $5.28B | $5.63B | $6.21B | $6.40B | $2.93B | $2.82B | $2.92B | $2.58B | $2.53B | $2.50B |
| Other Non-Current Liabilities | $4.37B | $4.63B | $7.94B | $7.62B | $8.15B | $7.23B | $7.63B | $8.24B | $8.50B | $9.44B | $10.73B | $11.58B | $13.01B | $13.20B | $9.64B | $9.63B | $10.49B | $10.53B | $10.13B | $9.48B |
| Total Non-Current Liabilities | $35.30B | $38.19B | $36.18B | $35.89B | $31.41B | $30.28B | $32.75B | $36.02B | $33.13B | $34.18B | $38.81B | $41.17B | $43.48B | $43.66B | $35.73B | $28.97B | $30.78B | $31.55B | $28.09B | $27.95B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $63.16B | $64.12B | $64.74B | $64.79B | $61.95B | $58.87B | $59.13B | $60.88B | $59.42B | $59.03B | $60.63B | $63.91B | $66.08B | $67.31B | $57.95B | $50.48B | $51.09B | $50.49B | $46.27B | $44.99B |
| Preferred Stock | $- | $- | $- | $- | $949.00M | $- | $- | $- | $1.62B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $388.00M | $388.00M | $388.00M | $388.00M | $388.00M | $387.00M | $387.00M | $387.00M | $387.00M | $387.00M | $387.00M | $387.00M | $387.00M | $387.00M | $328.00M | $328.00M | $328.00M | $328.00M | $328.00M | $328.00M |
| Retained Earnings | $3.16B | $3.14B | $1.85B | $-212.00M | $1.50B | $-434.00M | $-234.00M | $-1.82B | $-574.00M | $-2.47B | $-1.66B | $-1.23B | $1.71B | $2.20B | $5.33B | $4.09B | $5.30B | $1.88B | $1.91B | $448.00M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $2.08B | $2.08B | $-949.00M | $2.08B | $2.08B | $2.07B | $-1.62B | $2.08B | $2.07B | $2.05B | $111.00M | $2.04B | $2.03B | $2.04B | $881.00M | $2.04B | $2.05B | $2.06B |
| Other Total Stockholders Equity | $37.24B | $37.19B | $35.20B | $35.19B | $34.24B | $35.17B | $35.16B | $35.16B | $33.53B | $35.14B | $35.13B | $35.13B | $35.13B | $35.12B | $7.98B | $7.98B | $7.97B | $7.95B | $7.95B | $7.95B |
| Total Stockholders Equity | $40.79B | $40.72B | $39.51B | $37.45B | $39.14B | $37.20B | $37.39B | $35.79B | $37.04B | $35.13B | $35.93B | $36.34B | $39.27B | $39.74B | $15.68B | $14.43B | $15.62B | $12.20B | $12.24B | $10.78B |
| Total Equity | $40.87B | $40.80B | $39.60B | $37.50B | $39.17B | $37.22B | $37.42B | $35.81B | $37.06B | $35.15B | $35.95B | $36.36B | $39.29B | $39.91B | $15.69B | $14.45B | $15.64B | $13.62B | $13.66B | $12.22B |
| Total Liabilities and Stockholders Equity | $104.03B | $104.92B | $104.34B | $102.29B | $101.12B | $96.09B | $96.54B | $96.69B | $96.48B | $94.19B | $96.58B | $100.27B | $105.36B | $107.22B | $73.64B | $64.93B | $66.73B | $64.11B | $59.93B | $57.21B |
| Minority Interest | $85.00M | $86.00M | $86.00M | $56.00M | $23.00M | $24.00M | $24.00M | $22.00M | $21.00M | $20.00M | $19.00M | $19.00M | $19.00M | $168.00M | $17.00M | $16.00M | $16.00M | $1.42B | $1.42B | $1.44B |
| Total Liabilities and Total Equity | $104.03B | $104.92B | $104.34B | $102.29B | $101.12B | $96.09B | $96.54B | $96.69B | $96.48B | $94.19B | $96.58B | $100.27B | $105.36B | $107.22B | $73.64B | $64.93B | $66.73B | $64.11B | $59.93B | $57.21B |
| Total Investments | $1.90B | $2.15B | $1.87B | $1.70B | $1.68B | $1.29B | $1.14B | $1.23B | $1.14B | $1.10B | $1.18B | $1.24B | $1.24B | $1.58B | $1.12B | $1.06B | $1.15B | $1.22B | $1.62B | $1.52B |
| Total Debt | $30.11B | $31.56B | $33.53B | $34.55B | $28.62B | $28.58B | $29.84B | $31.50B | $29.23B | $29.30B | $29.53B | $31.10B | $30.78B | $31.91B | $27.50B | $20.13B | $20.38B | $22.34B | $19.75B | $18.58B |
| Net Debt | $24.63B | $26.77B | $26.62B | $26.71B | $22.78B | $23.70B | $24.17B | $25.27B | $23.07B | $24.84B | $24.71B | $25.34B | $24.45B | $24.84B | $11.93B | $12.50B | $12.55B | $14.27B | $14.07B | $15.16B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $8.69B | $6.90B | $2.50B | $-265.00M | $3.92B |
| Depreciation and Amortization | $6.69B | $4.93B | $5.48B | $6.53B | $3.15B |
| Deferred Income Tax | $- | $- | $-619.00M | $-615.00M | $-277.00M |
| Stock Based Compensation | $- | $579.00M | $619.00M | $615.00M | $277.00M |
| Change in Working Capital | $-893.00M | $300.00M | $3.76B | $2.02B | $361.00M |
| Accounts Receivables | $- | $-1.43B | $-1.35B | $-961.00M | $-739.00M |
| Inventory | $- | $-669.00M | $3.94B | $1.58B | $-621.00M |
| Accounts Payables | $- | $1.43B | $1.35B | $961.00M | $739.00M |
| Other Working Capital | $-893.00M | $969.00M | $-184.00M | $444.00M | $982.00M |
| Other Non Cash Items | $-2.62B | $-2.37B | $-1.93B | $-2.32B | $-2.63B |
| Net Cash Provided by Operating Activities | $11.86B | $10.35B | $9.81B | $5.96B | $4.80B |
| Investments in Property Plant and Equipment | $-1.92B | $-1.36B | $-2.57B | $-2.20B | $-2.61B |
| Acquisitions Net | $-3.93B | $-1.18B | $-1.06B | $-9.43B | $-830.00M |
| Purchases of Investments | $-96.00M | $-136.00M | $-159.00M | $-184.00M | $-119.00M |
| Sales Maturities of Investments | $108.00M | $129.00M | $42.00M | $105.00M | $2.13B |
| Other Investing Activities | $-2.14B | $-1.52B | $789.00M | $654.00M | $1.14B |
| Net Cash Used for Investing Activities | $-7.98B | $-4.06B | $-2.96B | $-11.06B | $-285.00M |
| Debt Repayment | $1.81B | $-965.00M | $-1.51B | $7.89B | $1.65B |
| Common Stock Issued | $-43.00M | $33.00M | $29.00M | $29.00M | $30.00M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $-4.63B | $-4.48B | $-4.36B | $-3.86B | $-3.57B |
| Other Financing Activities | $-1.13B | $-1.15B | $-973.00M | $-418.00M | $-308.00M |
| Net Cash Used Provided by Financing Activities | $-4.00B | $-6.57B | $-6.82B | $3.65B | $-2.20B |
| Effect of Forex Changes on Cash | $-93.00M | $-60.00M | $-80.00M | $-62.00M | $12.00M |
| Net Change in Cash | $-208.00M | $-346.00M | $-55.00M | $-1.51B | $2.32B |
| Cash at End of Period | $5.43B | $5.64B | $5.98B | $6.04B | $7.55B |
| Cash at Beginning of Period | $5.64B | $5.98B | $6.04B | $7.55B | $5.22B |
| Operating Cash Flow | $11.86B | $10.35B | $9.81B | $5.96B | $4.80B |
| Capital Expenditure | $-4.59B | $-3.78B | $-2.57B | $-2.20B | $-2.61B |
| Free Cash Flow | $7.28B | $6.57B | $7.24B | $3.76B | $2.19B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $1.67B | $1.83B | $1.93B | $2.80B | $897.00M | $1.65B | $2.09B | $2.26B | $778.00M | $923.00M | $247.00M | $553.00M | $-636.00M | $-2.00B | $764.00M | $1.61B | $1.17B | $853.00M | $961.00M | $935.00M |
| Depreciation and Amortization | $2.34B | $1.82B | $1.28B | $1.25B | $874.00M | $1.28B | $1.28B | $1.50B | $1.48B | $1.33B | $1.36B | $1.31B | $2.19B | $2.79B | $753.00M | $797.00M | $797.00M | $801.00M | $710.00M | $841.00M |
| Deferred Income Tax | $- | $- | $- | $- | $-579.00M | $- | $- | $- | $-619.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $579.00M | $- | $- | $- | $619.00M | $- | $- | $- | $615.00M | $- | $- | $- | $277.00M | $- | $- | $- |
| Change in Working Capital | $-350.00M | $41.00M | $-129.00M | $-455.00M | $150.00M | $897.00M | $-989.00M | $242.00M | $299.00M | $1.07B | $587.00M | $1.80B | $-42.00M | $1.21B | $-353.00M | $1.21B | $616.00M | $525.00M | $-335.00M | $-445.00M |
| Accounts Receivables | $- | $- | $- | $- | $-1.43B | $- | $- | $- | $-1.35B | $- | $- | $- | $-961.00M | $- | $- | $- | $-739.00M | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $-669.00M | $- | $- | $- | $3.94B | $- | $- | $- | $1.58B | $- | $- | $- | $-621.00M | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $2.39B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $-350.00M | $41.00M | $-129.00M | $-455.00M | $-150.00M | $897.00M | $-989.00M | $242.00M | $-2.29B | $1.07B | $587.00M | $1.80B | $-2.06B | $1.21B | $-353.00M | $1.21B | $255.00M | $525.00M | $-335.00M | $-445.00M |
| Other Non Cash Items | $-746.00M | $-303.00M | $8.00M | $-356.00M | $459.00M | $-717.00M | $-657.00M | $-873.00M | $-159.00M | $-394.00M | $-943.00M | $-434.00M | $-96.00M | $-274.00M | $-272.00M | $-1.68B | $-782.00M | $-357.00M | $-296.00M | $-1.19B |
| Net Cash Provided by Operating Activities | $2.91B | $3.38B | $3.08B | $2.49B | $2.38B | $3.11B | $1.72B | $3.13B | $2.40B | $2.93B | $1.25B | $3.23B | $1.42B | $1.72B | $892.00M | $1.93B | $1.80B | $1.82B | $1.04B | $139.00M |
| Investments in Property Plant and Equipment | $-708.00M | $-417.00M | $-382.00M | $-1.60B | $-946.00M | $-879.00M | $-483.00M | $-1.47B | $-554.00M | $-1.11B | $-543.00M | $-363.00M | $-718.00M | $-660.00M | $-353.00M | $-469.00M | $-548.00M | $-705.00M | $-977.00M | $-376.00M |
| Acquisitions Net | $-274.00M | $-281.00M | $-2.30B | $-940.00M | $-296.00M | $-273.00M | $-184.00M | $-426.00M | $-189.00M | $-342.00M | $-288.00M | $-242.00M | $-218.00M | $-9.63B | $-138.00M | $550.00M | $-159.00M | $-310.00M | $-186.00M | $-175.00M |
| Purchases of Investments | $- | $-29.00M | $31.00M | $-98.00M | $-15.00M | $-95.00M | $-26.00M | $- | $190.00M | $-321.00M | $-24.00M | $-4.00M | $6.00M | $-180.00M | $-10.00M | $249.00M | $185.00M | $477.00M | $-4.00M | $-115.00M |
| Sales Maturities of Investments | $-32.00M | $47.00M | $84.00M | $9.00M | $97.00M | $-68.00M | $81.00M | $19.00M | $- | $-2.00M | $-9.00M | $53.00M | $-15.00M | $-15.00M | $107.00M | $28.00M | $475.00M | $239.00M | $1.13B | $282.00M |
| Other Investing Activities | $-167.00M | $-834.00M | $-308.00M | $-1.05B | $83.00M | $94.00M | $92.00M | $631.00M | $304.00M | $33.00M | $64.00M | $388.00M | $32.00M | $18.00M | $158.00M | $197.00M | $185.00M | $-281.00M | $185.00M | $393.00M |
| Net Cash Used for Investing Activities | $-1.18B | $-1.51B | $-2.87B | $-2.41B | $-1.08B | $-1.22B | $-520.00M | $-1.25B | $-249.00M | $-1.74B | $-800.00M | $-168.00M | $-913.00M | $-10.46B | $-236.00M | $555.00M | $138.00M | $-580.00M | $148.00M | $9.00M |
| Debt Repayment | $-608.00M | $-2.42B | $-2.71B | $5.97B | $-236.00M | $-1.21B | $-1.44B | $1.92B | $-72.00M | $58.00M | $-1.24B | $-78.00M | $-905.00M | $1.60B | $7.34B | $-194.00M | $-1.66B | $2.47B | $1.18B | $-53.00M |
| Common Stock Issued | $23.00M | $-77.00M | $5.00M | $6.00M | $21.00M | $4.00M | $4.00M | $4.00M | $18.00M | $3.00M | $3.00M | $5.00M | $19.00M | $1.00M | $4.00M | $5.00M | $19.00M | $2.00M | $3.00M | $6.00M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $-3.00M | $-1.58B | $-17.00M | $-3.03B | $-2.00M | $-1.41B | $-22.00M | $-3.05B | $- | $-1.39B | $- | $-2.97B | $- | $-1.39B | $- | $-2.47B | $- | $-1.17B | $- | $-2.40B |
| Other Financing Activities | $-83.00M | $-59.00M | $1.50B | $-915.00M | $-74.00M | $-111.00M | $-62.00M | $-907.00M | $-304.00M | $-98.00M | $-60.00M | $-696.00M | $-165.00M | $-68.00M | $-60.00M | $-73.00M | $-570.00M | $-58.00M | $-54.00M | $83.00M |
| Net Cash Used Provided by Financing Activities | $-671.00M | $-4.13B | $-1.22B | $2.03B | $-291.00M | $-2.73B | $-1.52B | $-2.03B | $-358.00M | $-1.43B | $-1.29B | $-3.74B | $-1.05B | $142.00M | $7.29B | $-2.73B | $-2.21B | $1.24B | $1.13B | $-2.36B |
| Effect of Forex Changes on Cash | $-61.00M | $20.00M | $-6.00M | $-46.00M | $6.00M | $-19.00M | $-36.00M | $-11.00M | $6.00M | $-51.00M | $-26.00M | $-9.00M | $11.00M | $-21.00M | $15.00M | $-67.00M | $26.00M | $4.00M | $14.00M | $-32.00M |
| Net Change in Cash | $994.00M | $-2.24B | $-1.01B | $2.06B | $1.02B | $-852.00M | $-357.00M | $-155.00M | $1.80B | $-294.00M | $-873.00M | $-685.00M | $-535.00M | $-8.62B | $7.96B | $-309.00M | $-248.00M | $2.49B | $2.33B | $-2.25B |
| Cash at End of Period | $5.43B | $4.43B | $6.68B | $7.69B | $5.64B | $4.62B | $5.47B | $5.83B | $5.98B | $4.19B | $4.48B | $5.35B | $6.04B | $6.57B | $15.20B | $7.24B | $7.55B | $7.79B | $5.30B | $2.98B |
| Cash at Beginning of Period | $4.43B | $6.68B | $7.69B | $5.64B | $4.62B | $5.47B | $5.83B | $5.98B | $4.19B | $4.48B | $5.35B | $6.04B | $6.57B | $15.20B | $7.24B | $7.55B | $7.79B | $5.30B | $2.98B | $5.22B |
| Operating Cash Flow | $2.91B | $3.38B | $3.08B | $2.49B | $2.38B | $3.11B | $1.72B | $3.13B | $2.40B | $2.93B | $1.25B | $3.23B | $1.42B | $1.72B | $892.00M | $1.93B | $1.80B | $1.82B | $1.04B | $139.00M |
| Capital Expenditure | $-955.00M | $-1.36B | $-668.00M | $-1.60B | $-946.00M | $-879.00M | $-483.00M | $-1.47B | $-554.00M | $-1.11B | $-543.00M | $-363.00M | $-718.00M | $-660.00M | $-353.00M | $-469.00M | $-548.00M | $-705.00M | $-977.00M | $-376.00M |
| Free Cash Flow | $1.95B | $2.02B | $2.42B | $881.00M | $1.43B | $2.23B | $1.24B | $1.66B | $1.84B | $1.82B | $705.00M | $2.87B | $700.00M | $1.06B | $539.00M | $1.47B | $1.25B | $1.12B | $63.00M | $-237.00M |
AstraZeneca PLC Dividends
Explore AstraZeneca PLC's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
2.27%
Dividend Payout Ratio
65.80%
Dividend Paid & Capex Coverage Ratio
1.29x
AstraZeneca PLC Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $132.8964 | $132.8964 | February 20, 2025 | February 21, 2025 | March 24, 2025 | |
| $60.81512 | $60.81512 | August 08, 2024 | August 09, 2024 | September 09, 2024 | |
| $123.25326 | $123.25326 | February 22, 2024 | February 23, 2024 | March 25, 2024 | |
| $56.53532 | $56.53532 | August 10, 2023 | August 11, 2023 | September 11, 2023 | |
| $135.30145 | $135.30145 | February 23, 2023 | February 24, 2023 | March 27, 2023 | |
| $76.4 | $62.90152 | August 11, 2022 | August 12, 2022 | September 12, 2022 | July 29, 2022 |
| $108.01021 | $108.01021 | February 24, 2022 | February 25, 2022 | March 28, 2022 | February 10, 2022 |
| $46.8166 | $46.8166 | August 12, 2021 | August 13, 2021 | September 13, 2021 | July 29, 2021 |
| $97.99551 | $97.99551 | February 25, 2021 | February 26, 2021 | March 29, 2021 | February 11, 2021 |
| $53.25572 | $53.25572 | August 13, 2020 | August 14, 2020 | September 14, 2020 | October 24, 2019 |
| $113.71571 | $113.71571 | February 27, 2020 | February 28, 2020 | March 30, 2020 | October 24, 2019 |
| $59.32553 | $59.32553 | August 08, 2019 | August 09, 2019 | September 09, 2019 | November 08, 2018 |
| $110.82177 | $110.82177 | February 28, 2019 | March 01, 2019 | March 27, 2019 | November 08, 2018 |
| $53.28622 | $53.28622 | August 09, 2018 | August 10, 2018 | September 10, 2018 | November 09, 2017 |
| $95.28129 | $95.28129 | February 15, 2018 | February 16, 2018 | March 19, 2018 | November 09, 2017 |
| $53.05369 | $53.05369 | August 10, 2017 | August 11, 2017 | September 11, 2017 | February 02, 2017 |
| $120.50896 | $120.50896 | February 16, 2017 | February 17, 2017 | March 20, 2017 | November 16, 2016 |
| $53.03068 | $53.03068 | August 11, 2016 | August 12, 2016 | September 12, 2016 | February 04, 2016 |
| $91.58712 | $91.58712 | February 18, 2016 | February 19, 2016 | March 21, 2016 | February 04, 2016 |
| $36.84006 | $36.84006 | August 13, 2015 | August 14, 2015 | September 14, 2015 | July 30, 2015 |
AstraZeneca PLC News
Read the latest news about AstraZeneca PLC, including recent articles, headlines, and updates.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for AZN.L.